tiprankstipranks
Trending News
More News >
Abivax SA Sponsored ADR (ABVX)
NASDAQ:ABVX
US Market
Advertisement

Abivax SA Sponsored ADR (ABVX) AI Stock Analysis

Compare
184 Followers

Top Page

ABVX

Abivax SA Sponsored ADR

(NASDAQ:ABVX)

Rating:49Neutral
Price Target:
$68.00
▼(-4.01%Downside)
Abivax SA's overall stock score is primarily impacted by its poor financial performance, characterized by operational losses and high leverage. While technical analysis shows bullish momentum, the valuation remains unattractive due to negative earnings. Without additional positive catalysts or improvements in profitability, the stock faces significant risks.
Positive Factors
Clinical Trial Success
Positive topline induction results from the Phase 3 ABTECT program for lead program obefazimod in ulcerative colitis.
Market Potential
Obefazimod now has the most compelling late-stage clinical profile for a novel oral agent in ulcerative colitis with potential to address a clear unmet need in the massive ~$30bn market for IBD therapeutics.
Regulatory Prospects
Both doses of obefazimod met European Medicines Agency co-primary endpoints, strengthening confidence in the potential for regulatory approval.
Negative Factors
Dose Efficacy
The lower 25mg QD dose was not statistically significant on clinical remission in ABTECT-2, although other relevant endpoints were significant.

Abivax SA Sponsored ADR (ABVX) vs. SPDR S&P 500 ETF (SPY)

Abivax SA Sponsored ADR Business Overview & Revenue Model

Company DescriptionAbivax SA Sponsored ADR (ABVX) is a biotechnology company focused on developing therapies for inflammatory diseases, viral infections, and cancer. The company's core products are centered around its proprietary drug candidates, which are designed to modulate the immune response in patients. Abivax operates primarily in the biopharmaceutical sector, leveraging its research and development capabilities to bring innovative solutions to market.
How the Company Makes MoneyAbivax makes money through the development and commercialization of its drug candidates. The company generates revenue primarily through strategic partnerships, licensing agreements, and milestone payments from collaborations with other pharmaceutical companies. These partnerships often involve the co-development and co-commercialization of Abivax's drug candidates, providing the company with upfront payments, research funding, and potential royalties on future sales. Additionally, Abivax may receive government grants and research funding to support its R&D activities, which can contribute to its earnings.

Abivax SA Sponsored ADR Financial Statement Overview

Summary
Abivax SA faces significant financial challenges with consistent operational losses and reliance on debt financing. Despite revenue growth, profitability remains a concern with high operating losses and negative cash flows, indicating a need for strategic improvements.
Income Statement
30
Negative
The company has shown significant revenue growth from the previous year, but still operates at a loss with negative net profit and EBIT margins. The gross profit margin remains stable, yet the high negative EBIT and net income suggest ongoing operational challenges.
Balance Sheet
40
Negative
The company's balance sheet indicates high leverage with a substantial debt-to-equity ratio, but it has managed to maintain a reasonable equity ratio. The return on equity remains negative due to continued losses, suggesting difficulty in generating shareholder value.
Cash Flow
35
Negative
Cash flow from operations is negative, reflecting operational struggles, although there is positive free cash flow growth due to reduced capital expenditures. The company relies heavily on financing activities to manage its cash needs, indicating potential liquidity risks.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue10.79M4.62M4.58M37.00K63.00K
Gross Profit10.79M4.57M4.47M-119.00K-33.77M
EBITDA-171.88M-133.21M-53.31M-38.59M-38.00M
Net Income-176.24M-147.74M-60.74M-42.45M-37.55M
Balance Sheet
Total Assets205.23M327.06M75.54M109.23M71.30M
Cash, Cash Equivalents and Short-Term Investments144.22M260.99M26.95M60.70M29.30M
Total Debt97.36M55.46M49.23M51.65M33.99M
Total Liabilities164.64M131.05M68.36M83.30M53.40M
Stockholders Equity40.58M196.01M7.19M25.93M17.90M
Cash Flow
Free Cash Flow-154.72M-100.28M-54.26M-47.30M-30.72M
Operating Cash Flow-154.07M-100.01M-53.94M-45.66M-29.82M
Investing Cash Flow15.76M-10.49M-12.03M-1.46M-575.00K
Financing Cash Flow28.21M340.57M32.21M78.51M49.93M

Abivax SA Sponsored ADR Technical Analysis

Technical Analysis Sentiment
Positive
Last Price70.84
Price Trends
50DMA
16.10
Positive
100DMA
11.26
Positive
200DMA
9.68
Positive
Market Momentum
MACD
17.03
Negative
RSI
93.62
Negative
STOCH
95.37
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABVX, the sentiment is Positive. The current price of 70.84 is above the 20-day moving average (MA) of 30.02, above the 50-day MA of 16.10, and above the 200-day MA of 9.68, indicating a bullish trend. The MACD of 17.03 indicates Negative momentum. The RSI at 93.62 is Negative, neither overbought nor oversold. The STOCH value of 95.37 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABVX.

Abivax SA Sponsored ADR Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
¥354.29B10.98-2.99%2.48%11.72%-10.32%
54
Neutral
$644.06M-49.91%-14.16%25.88%
49
Neutral
$5.19B-147.48%18.47%
44
Neutral
$1.50B-115.39%-4.14%
43
Neutral
$407.60M-247.05%-82.41%
43
Neutral
$940.88M-48.45%7.15%
34
Underperform
$439.10M-45.82%10.38%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ABVX
Abivax SA Sponsored ADR
70.84
59.08
502.38%
CELC
Celcuity
39.16
21.22
118.28%
AUTL
Autolus Therapeutics
2.49
-2.02
-44.79%
ORIC
Oric Pharmaceuticals
10.71
0.10
0.94%
ERAS
Erasca
1.55
-1.52
-49.51%
ALMS
Alumis Inc.
4.10
-8.59
-67.69%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 24, 2025